Go-To-Market (GTM) initiatives, in medical diagnostic, medical device, life science tools, digital health, and healthcare service companies, are strategically critical in determining company success. Yet companies frequently underestimate the challenge. Mistakes can be costly, even catastrophic.
GTM preparedness and performance directly impact all key value creation moments throughout a company’s existence.
The quality of GTM plans and performance will be the dominant factor that helps or hinders company valuations in equity, partnership, and M&A transactions.
Nothing a management team does will impact the future of the company more than its GTM initiatives. That is why our GTM Advisory Services™, including the PowerLab™, are essential.
Dominant GTM operating performance shows up in revenue, margin, profit, and cash flow metrics. It requires simultaneous delivery of better, faster, and more cost-efficient operating results, with GTM activities beginning early in development and continuing aggressively and adaptively across the Commercial Spectrum™.
Only when these goals are met can pre-launch GTM activities be optimized, the course of under-performing products be corrected, acceptable GTM performance be sustained, and higher growth rates be realized.
No less important, GTM plans and performance are the crux of due diligence for strategic initiatives such as financings, strategic partnership transactions, and M&A deals, showing up eventually in company valuation metrics.
GTM success requires overcoming three central challenges, to enable delivery of products deeply valued by the market in a timely and cost-competitive way, as well as to close strategic deals successfully.
GTM challenges, which frequently have been added to people’s existing organizational responsibilities, can be overwhelming – even for experienced executives.
Clarity from our GTM Advisory Services™, including the PowerLab™, drive impact on both operating performance and strategic deal results.